TNFSF10 and neoplasm: Therefore, the drug delivery of TRAIL limited by poor pharmacokinetics, together with induced TRAIL resistance of tumor cells, probably were the major reasons of the withdrawing of TRAIL from Amgen and Genentech pipelines14.